cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25402/nnm.24278875
title: Ternary nanocomposite potentiates the lysophosphatidic acid effect on human osteoblast (MG63) maturation - supplementary data

description: <b>Aim: </b>This study aimed to investigate the potential of ternary nanocomposite (TNC) to support MG63 osteoblast maturation to EB1089-(3S)1-fluoro-3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP) cotreatment. <b>Materials & methods: </b>Binary (P25<b>/</b>reduced graphene oxide [rGO]) nanocomposite was prepared, and silver (Ag) nanoparticles were loaded onto the surface to form TNC (P25<b>/</b>rGO<b>/</b>Ag). The influence of TNC on proliferation, alkaline phosphatase activity and osteogenic gene expression was evaluated in a model of osteoblast maturation wherein MG63 were costimulated with EB1089 and FHBP. <b>Results: </b>TNC had no cytotoxic effect onMG63. The addition of TNC to EB1089-FHBP cotreatment enhanced the maturation of MG63, as supported by the greater alkaline phosphatase activity and <i>OPN </i>and <i>OCN </i>gene expression. <b>Conclusion: </b>TNC could serve as a promising carrier for FHBP, opening up possibilities for its application in bone regeneration.<b>Plain language summary: </b>Nanoparticles (NPs) are often used in medicine because they have certain benefits over traditional drugs, such as increased delivery. Multiple NPs can be combined into hybrid NPs called nanocomplexes, which can have many positive effects. One application of nanomedicine is to encourage the repair of certain body tissues such as bones. Encouraging stem cells to differentiate into bone cells and immature bone cells to mature is key in this process. This study made a ternary nanocomplex (TNC), meaning it was comprised of three NPs. This TNC was designed to deliver a drug called (3S)1-fluoro- 3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP), which has been shown to encourage the maturation and development of osteoblasts, a type of bone cell. The TNC was made up of silver NPs, which can kill bacteria; reduced graphene oxide, which enhances the production of bone cells; and titanium dioxide, which has shown effectiveness in wound healing and mixed results in bone tissue regeneration. This TNC was tested on a cell line that comes from a type of bone cancer called MG63. The TNC was found to not be toxic to these cells. TNC incorporation into FHBP treatment enhanced the maturation of MG63. This suggests that these TNCs could be an effective treatment to encourage bone repair following joint replacement surgeries.
DOI: 10.25549/examiner-c44-17894
title: Fiesta, 1951

description: 23 images. Fiesta, 2 August 1951. Jose Manero (Dance Director); Paquita del Rey; Kay Chapman; Marjorie Hall; Frater August; Frater Carroll; Pattye Reily; Ann Lamb; Connie Harder; Chantal de Lendonck; Mr. and Mrs. Francis Price; Joann Cobb; Beverly Agnew; Lois Byllesby; Mrs. Diane Noble; Mrs. William Sears; Jane Manning; Cynthia Wood; Mrs. F. Bertram Zener; Helen Andros; Sally Libke; Mary Kay Martz; Mrs. Ralph Raddue; Marleen Anderson; Mrs. Paul Trent; Royle Dawn Baker; Sue Trent; Robyn Baker.; Caption slip reads: "Photographer: Jensen. Date: 1951-08-01. Reporter: Horn. Assignment: Fiesta. 3-4: Miss Chantal de Lendonck; Mrs. Francis Price; 7-8: Mrs. Francis Price; Miss Joann Cobb. 9-10: Mr. & Mrs. Francis Price. 11-12: Mrs. Diane Noble; Mrs. William Sears;; Miss Jane Manning; Miss Cynthia Wood. 5: Mrs. Diane Noble; Miss Jane Manning. 37-38: Frater August, Frater Carroll, Jose, Paquita, Pattye Reily, Ann Lamb, Connie Harder. 64-65: Mrs. Ralph Raddue; Miss Marleen Anderson; Mrs. Paul Trent; Miss Royle Dawn Baker; Miss Sue Trent; Miss Robyn Baker. 67-68: Beverly Agnew; Lois Byllesby. 6, 102-103: Mrs. F. Bertram Zener; Miss Helen Andros; Miss Sally Libke; Miss Mary Kay Martz (standing). 68-69: Miss Helen Andros; Miss Mary Kay Martz (standing); Miss Sally Libke".
DOI: 10.25402/nnm.24278875.v1
title: Ternary nanocomposite potentiates the lysophosphatidic acid effect on human osteoblast (MG63) maturation - supplementary data

description: <b>Aim: </b>This study aimed to investigate the potential of ternary nanocomposite (TNC) to support MG63 osteoblast maturation to EB1089-(3S)1-fluoro-3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP) cotreatment. <b>Materials & methods: </b>Binary (P25<b>/</b>reduced graphene oxide [rGO]) nanocomposite was prepared, and silver (Ag) nanoparticles were loaded onto the surface to form TNC (P25<b>/</b>rGO<b>/</b>Ag). The influence of TNC on proliferation, alkaline phosphatase activity and osteogenic gene expression was evaluated in a model of osteoblast maturation wherein MG63 were costimulated with EB1089 and FHBP. <b>Results: </b>TNC had no cytotoxic effect onMG63. The addition of TNC to EB1089-FHBP cotreatment enhanced the maturation of MG63, as supported by the greater alkaline phosphatase activity and <i>OPN </i>and <i>OCN </i>gene expression. <b>Conclusion: </b>TNC could serve as a promising carrier for FHBP, opening up possibilities for its application in bone regeneration.<b>Plain language summary: </b>Nanoparticles (NPs) are often used in medicine because they have certain benefits over traditional drugs, such as increased delivery. Multiple NPs can be combined into hybrid NPs called nanocomplexes, which can have many positive effects. One application of nanomedicine is to encourage the repair of certain body tissues such as bones. Encouraging stem cells to differentiate into bone cells and immature bone cells to mature is key in this process. This study made a ternary nanocomplex (TNC), meaning it was comprised of three NPs. This TNC was designed to deliver a drug called (3S)1-fluoro- 3-hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP), which has been shown to encourage the maturation and development of osteoblasts, a type of bone cell. The TNC was made up of silver NPs, which can kill bacteria; reduced graphene oxide, which enhances the production of bone cells; and titanium dioxide, which has shown effectiveness in wound healing and mixed results in bone tissue regeneration. This TNC was tested on a cell line that comes from a type of bone cancer called MG63. The TNC was found to not be toxic to these cells. TNC incorporation into FHBP treatment enhanced the maturation of MG63. This suggests that these TNCs could be an effective treatment to encourage bone repair following joint replacement surgeries.
DOI: 10.25402/nnm.24305833
title: Nanoarchitectonics of doxycycline-loaded vitamin E–D-α-tocopheryl polyethylene glycol 1000 succinate micelles for ovarian cancer stem cell treatment - supplementary data

description: <b>Aim: </b>This study aim to develop doxycycline within the D-<b>α</b>-tocopheryl polyethylene glycol 1000 succinate micelle platform as an anticancer stem cell agent. <b>Materials & methods: </b>The optimized nanomicelle formulation was prepared using the solvent casting method and evaluated through physicochemical and biological characterization. <b>Results: </b>Nanomicelles exhibited mean particle sizes of 14.48 nm (polydispersity index: 0.22) using dynamic light scattering and 18.22 nm using transmission electron micrography. Drug loading and encapsulation efficiency were 2% and 66.73%, respectively. Doxycycline-loaded micelles exhibited sustained release, with 98.5% released in 24 h. IC50 values were 20 μg<b>/</b>ml for free drug and 5 μg<b>/</b>ml for micelles after 48 h of cell exposure. A significant 74% reduction in CD44 biomarker and 100% colony formation inhibition were observed. <b>Conclusion: </b>Doxycycline in hemo<b>/</b>biocompatible nanomicelles holds potential for ovarian cancer stem cell therapy.
DOI: 10.25402/nnm.24305833.v1
title: Nanoarchitectonics of doxycycline-loaded vitamin E–D-α-tocopheryl polyethylene glycol 1000 succinate micelles for ovarian cancer stem cell treatment - supplementary data

description: <b>Aim: </b>This study aim to develop doxycycline within the D-<b>α</b>-tocopheryl polyethylene glycol 1000 succinate micelle platform as an anticancer stem cell agent. <b>Materials & methods: </b>The optimized nanomicelle formulation was prepared using the solvent casting method and evaluated through physicochemical and biological characterization. <b>Results: </b>Nanomicelles exhibited mean particle sizes of 14.48 nm (polydispersity index: 0.22) using dynamic light scattering and 18.22 nm using transmission electron micrography. Drug loading and encapsulation efficiency were 2% and 66.73%, respectively. Doxycycline-loaded micelles exhibited sustained release, with 98.5% released in 24 h. IC50 values were 20 μg<b>/</b>ml for free drug and 5 μg<b>/</b>ml for micelles after 48 h of cell exposure. A significant 74% reduction in CD44 biomarker and 100% colony formation inhibition were observed. <b>Conclusion: </b>Doxycycline in hemo<b>/</b>biocompatible nanomicelles holds potential for ovarian cancer stem cell therapy.
DOI: 10.25402/nnm.24305866
title: CD44 targeted delivery of hyaluronic-acid-coated polymeric nanoparticles against colorectal cancer supplementary data

description: Aim: To develop hyaluronic acid (HA)-coated poly-lactic-co-glycolic acid (PLGA)-polysarcosine (PSAR) coupled sorafenib tosylate (SF) polymeric nanoparticles for targeted colon cancer therapy. Materials & methods: PLGA–PSAR shells were encapsulated with SF via nanoprecipitation. Interactions were examined with transmission electron microscopy, revealing formulation component interactions. Results: The optimized HA-coated polymeric nanoparticles (238.8 nm, -6.1 mV, 68.361% entrapment) displayed enhanced controlled release of SF. These formulations showed superior cytotoxicity against HCT116 cell lines compared with free drug (p &lt; 0.05). In vivo tests on male albino Wistar rats demonstrated improved pharmacokinetics, targeting and biocompatibility. HA-coated PLGA–PSAR-coupled SF polymeric nanoparticles hold potential for effective colorectal therapy. Conclusion: Colon cancer may be precisely targeted by HA-coated PLGA–PSA-coupled SF polymeric nanoparticles.
DOI: 10.25402/nnm.24305866.v1
title: CD44 targeted delivery of hyaluronic-acid-coated polymeric nanoparticles against colorectal cancer supplementary data

description: Aim: To develop hyaluronic acid (HA)-coated poly-lactic-co-glycolic acid (PLGA)-polysarcosine (PSAR) coupled sorafenib tosylate (SF) polymeric nanoparticles for targeted colon cancer therapy. Materials & methods: PLGA–PSAR shells were encapsulated with SF via nanoprecipitation. Interactions were examined with transmission electron microscopy, revealing formulation component interactions. Results: The optimized HA-coated polymeric nanoparticles (238.8 nm, -6.1 mV, 68.361% entrapment) displayed enhanced controlled release of SF. These formulations showed superior cytotoxicity against HCT116 cell lines compared with free drug (p &lt; 0.05). In vivo tests on male albino Wistar rats demonstrated improved pharmacokinetics, targeting and biocompatibility. HA-coated PLGA–PSAR-coupled SF polymeric nanoparticles hold potential for effective colorectal therapy. Conclusion: Colon cancer may be precisely targeted by HA-coated PLGA–PSA-coupled SF polymeric nanoparticles.
DOI: 10.25402/nnm.24440848
title: Characterization and quantification of AAV capsid loading states by multi-wavelength AUC with UltraScan - supplementary material

description: SF 1: Spectral deconvolution fits for the MW data of AAV8 at scan 35SF 2: Screen shot of the spectral decomposition residual plot in UltraScan demonstrating the fit and residuals at individual radius positions for all wavelengths measured for AAV8.SF 3: Extinction spectrum for AAV5 capsid protein (blue) and DNA (red) between 230-310 nm. Absorbance spectra are normalized for to have the same area under each curve.SF 4: Sample quantity requirements – SV vs. ABDE. Required sample amounts are proportional to the orange shaded regions in an SV experiment (top) and an ABDE experiment (bottom). Since ADE experiments collect the entire signal only in the peak area, sample amounts are significantly reduced. In both experiments, the dynamic range of the detector must be observed to insure a linear response. In the case shown here, the amount of sample required for an ABDE experiment is 23.7 fold lower than in the SV experiment when integrating the orange area for both plots. This ratio increases if fewer peaks are observed, or decreases when additional peaks are observed.
DOI: 10.25402/nnm.24440848.v1
title: Characterization and quantification of AAV capsid loading states by multi-wavelength AUC with UltraScan - supplementary material

description: SF 1: Spectral deconvolution fits for the MW data of AAV8 at scan 35SF 2: Screen shot of the spectral decomposition residual plot in UltraScan demonstrating the fit and residuals at individual radius positions for all wavelengths measured for AAV8.SF 3: Extinction spectrum for AAV5 capsid protein (blue) and DNA (red) between 230-310 nm. Absorbance spectra are normalized for to have the same area under each curve.SF 4: Sample quantity requirements – SV vs. ABDE. Required sample amounts are proportional to the orange shaded regions in an SV experiment (top) and an ABDE experiment (bottom). Since ADE experiments collect the entire signal only in the peak area, sample amounts are significantly reduced. In both experiments, the dynamic range of the detector must be observed to insure a linear response. In the case shown here, the amount of sample required for an ABDE experiment is 23.7 fold lower than in the SV experiment when integrating the orange area for both plots. This ratio increases if fewer peaks are observed, or decreases when additional peaks are observed.
DOI: 10.25549/examiner-c44-16955
title: University of California Los Angeles Gridders at the beach, 1951

description: 6 images. University of California Los Angeles Gridders at the beach, 07 August 1951. Herb Lane; Larry Britten; Julie Weisstein; Bob Moore.; Caption slip reads: "Photographer: Jensen. Assignment: UCLA football plaers at beach. Herb Lane (E), San Francisco; Larry Britten (T), Redland; Julie Weisstein (Q), Beverly Hills; Bob Moore (LH), Los Angeles".
DOI: 10.25402/nnm.24517150
title: A new application of nano-selenium: rescue of CK2 and mitochondria from oxidative stress to prevent cardiac hypertrophy supplementary data

description: <b>Background: </b>Excessive reactive oxygen species (ROS) and subsequent mitochondrial dysfunction are pivotal in initiating cardiac hypertrophy. To explore nano-selenium’s (SeNP’s) preventive potential against this condition, the authors evaluated chemically synthesized chitosan-SeNPs and biosynthesized <i>Bacillus cereus </i>YC-3-SeNPs in an angiotensin II (Ang II)-induced cardiac hypertrophy model. <b>Methods: </b>This investigation encompassed ROS measurement, mitochondrial membrane potential analysis, transmission electron microscopy, gene and protein expression analyses, protein carbonylation assays, serum antioxidant quantification and histological staining. <b>Results: </b>SeNPs effectively countered Ang II-induced cardiac hypertrophy by reducing ROS, restoring mitochondrial and protein kinase 2<b>α </b>(CK2-<b>α</b>) function, activating antioxidant pathways and enhancing serum antioxidant levels. <b>Conclusion: </b>This finding underscores SeNPs’ role in attenuating Ang II-induced myocardial hypertrophy both <i>in vitro </i>and <i>in vivo</i>.<b>Plain language summary: </b>Enlargement of the heart is called cardiac hypertrophy; this is caused by too many reactive oxygen species, which are compounds that damage the mitochondria of cells. The mitochondria provide energy to cells and their disruption can cause a significantly negative effect on cells and the tissues and organs cells make up. Selenium is a type of metal that must be consumed in small amounts to stay healthy; it has antioxidant effects, meaning it can stop reactive oxygen species and potentially prevent cardiac hypertrophy. Nano-selenium (SeNP), consisting of tiny, spherical particles containing selenium, may be a more effective way of delivering selenium as an antioxidant to prevent cardiac hypertrophy. SeNPs were made synthetically and from a type of bacterium called <i>Bacillus cereus; </i>both SeNPs demonstrated antioxidant effects in heart cells taken from chicken embryos and live chickens. These results suggest that SeNPs could be developed into medication to combat cardiac hypertrophy.
DOI: 10.25402/nnm.24517150.v1
title: A new application of nano-selenium: rescue of CK2 and mitochondria from oxidative stress to prevent cardiac hypertrophy supplementary data

description: <b>Background: </b>Excessive reactive oxygen species (ROS) and subsequent mitochondrial dysfunction are pivotal in initiating cardiac hypertrophy. To explore nano-selenium’s (SeNP’s) preventive potential against this condition, the authors evaluated chemically synthesized chitosan-SeNPs and biosynthesized <i>Bacillus cereus </i>YC-3-SeNPs in an angiotensin II (Ang II)-induced cardiac hypertrophy model. <b>Methods: </b>This investigation encompassed ROS measurement, mitochondrial membrane potential analysis, transmission electron microscopy, gene and protein expression analyses, protein carbonylation assays, serum antioxidant quantification and histological staining. <b>Results: </b>SeNPs effectively countered Ang II-induced cardiac hypertrophy by reducing ROS, restoring mitochondrial and protein kinase 2<b>α </b>(CK2-<b>α</b>) function, activating antioxidant pathways and enhancing serum antioxidant levels. <b>Conclusion: </b>This finding underscores SeNPs’ role in attenuating Ang II-induced myocardial hypertrophy both <i>in vitro </i>and <i>in vivo</i>.<b>Plain language summary: </b>Enlargement of the heart is called cardiac hypertrophy; this is caused by too many reactive oxygen species, which are compounds that damage the mitochondria of cells. The mitochondria provide energy to cells and their disruption can cause a significantly negative effect on cells and the tissues and organs cells make up. Selenium is a type of metal that must be consumed in small amounts to stay healthy; it has antioxidant effects, meaning it can stop reactive oxygen species and potentially prevent cardiac hypertrophy. Nano-selenium (SeNP), consisting of tiny, spherical particles containing selenium, may be a more effective way of delivering selenium as an antioxidant to prevent cardiac hypertrophy. SeNPs were made synthetically and from a type of bacterium called <i>Bacillus cereus; </i>both SeNPs demonstrated antioxidant effects in heart cells taken from chicken embryos and live chickens. These results suggest that SeNPs could be developed into medication to combat cardiac hypertrophy.
DOI: 10.25402/nnm.24517177
title: Nano-ciprofloxacin/meropenem exhibit bactericidal activity against Gram-negative bacteria and rescue septic rat model supplementary data

description: <b>Aim: </b>We hypothesized that simultaneous administration of two antibiotics loaded into a nanopolymer matrix would augment their synergistic bactericidal interaction. <b>Methods: </b>Nanoplatforms of chitosan<b>/</b>Pluronic R <i>_ </i>loaded with ciprofloxacin<b>/</b>meropenem (CS<b>/</b>Plu-Cip<b>/</b>Mer) were prepared by the ionic gelation method, using Plu at concentrations in the range 0.5–4% w<b>/</b>v. CS<b>/</b>Plu-Cip<b>/</b>Mer was evaluated for antibacterial synergistic activity <i>in vitro </i>and <i>in vivo</i>. <b>Results: </b>CS<b>/</b>Plu-Cip and CS<b>/</b>Plu-Mer with Plu concentrations of 3% w<b>/</b>v and 2% w<b>/</b>v, respectively, exhibited <b>∼</b>80% encapsulation efficiency. The MICs of pathogens were fourfold to 16-fold lower for CS<b>/</b>Plu-Cip<b>/</b>Mer than for Cip<b>/</b>Mer. Synergy was evidenced for CS<b>/</b>Plu-Cip<b>/</b>Mer with a bactericidal effect (at 1<b>× </b>MIC and sub-MICs), and it significantly decreased bacterial load and rescued infected rats. <b>Conclusion: </b>This study illustrates the ability of CS<b>/</b>Plu nanopolymer to intensify synergy between antibiotics, thereby providing a promising potential to rejuvenate antibiotics considered ineffective against resistant pathogens.<b>Plain language summary: </b>Antibiotics are used to treat bacterial infections. However, the more they are used, the less effective they become, because bacteria develop resistance to them. One strategy to overcome this is to treat bacterial infection with a combination of antibiotics that work well together. The antibiotics ciprofloxacin and meropenem are often given together to treat <i>Pseudomonas aeruginosa</i>, a bacterium which can cause sepsis, a type of blood poisoning. Another strategy to overcome antibiotic resistance is to load them into nanocarriers, which can change their properties. Nanocarrier-loaded antibiotics can reduce toxicity and increase effectiveness. This study investigated whether the effectiveness of this pair could be improved by loading them into nanoparticles. When these nanoparticles were given to rats with sepsis, they were significantly more effective than unloaded ciprofloxacin and meropenem combinations. These nanoparticles were also able to directly kill bacteria, rather than just prevent bacterial reproduction, as with the unloaded combination. This study demonstrates that nanocarrier loading can intensify the enhanced benefit of combined antibiotic treatments. This is a promising strategy to reuse antibiotics that have become ineffective at treating bacteria which have developed resistance.
DOI: 10.25402/nnm.24517177.v1
title: Nano-ciprofloxacin/meropenem exhibit bactericidal activity against Gram-negative bacteria and rescue septic rat model supplementary data

description: <b>Aim: </b>We hypothesized that simultaneous administration of two antibiotics loaded into a nanopolymer matrix would augment their synergistic bactericidal interaction. <b>Methods: </b>Nanoplatforms of chitosan<b>/</b>Pluronic R <i>_ </i>loaded with ciprofloxacin<b>/</b>meropenem (CS<b>/</b>Plu-Cip<b>/</b>Mer) were prepared by the ionic gelation method, using Plu at concentrations in the range 0.5–4% w<b>/</b>v. CS<b>/</b>Plu-Cip<b>/</b>Mer was evaluated for antibacterial synergistic activity <i>in vitro </i>and <i>in vivo</i>. <b>Results: </b>CS<b>/</b>Plu-Cip and CS<b>/</b>Plu-Mer with Plu concentrations of 3% w<b>/</b>v and 2% w<b>/</b>v, respectively, exhibited <b>∼</b>80% encapsulation efficiency. The MICs of pathogens were fourfold to 16-fold lower for CS<b>/</b>Plu-Cip<b>/</b>Mer than for Cip<b>/</b>Mer. Synergy was evidenced for CS<b>/</b>Plu-Cip<b>/</b>Mer with a bactericidal effect (at 1<b>× </b>MIC and sub-MICs), and it significantly decreased bacterial load and rescued infected rats. <b>Conclusion: </b>This study illustrates the ability of CS<b>/</b>Plu nanopolymer to intensify synergy between antibiotics, thereby providing a promising potential to rejuvenate antibiotics considered ineffective against resistant pathogens.<b>Plain language summary: </b>Antibiotics are used to treat bacterial infections. However, the more they are used, the less effective they become, because bacteria develop resistance to them. One strategy to overcome this is to treat bacterial infection with a combination of antibiotics that work well together. The antibiotics ciprofloxacin and meropenem are often given together to treat <i>Pseudomonas aeruginosa</i>, a bacterium which can cause sepsis, a type of blood poisoning. Another strategy to overcome antibiotic resistance is to load them into nanocarriers, which can change their properties. Nanocarrier-loaded antibiotics can reduce toxicity and increase effectiveness. This study investigated whether the effectiveness of this pair could be improved by loading them into nanoparticles. When these nanoparticles were given to rats with sepsis, they were significantly more effective than unloaded ciprofloxacin and meropenem combinations. These nanoparticles were also able to directly kill bacteria, rather than just prevent bacterial reproduction, as with the unloaded combination. This study demonstrates that nanocarrier loading can intensify the enhanced benefit of combined antibiotic treatments. This is a promising strategy to reuse antibiotics that have become ineffective at treating bacteria which have developed resistance.